Gapping up
In reaction to strong earnings/guidance: WGO +11.1%, MLHR +6.7%, (raises dividend 5%), .ACN +1.7%, CMC +0.8%
M&A news: JOEZ +30.6% (PE takeover speculation), MSO +6.3% (may have 5 other bidders looking at the company, according to NYPost)
Select EU related names showing strength: SAN +2%, ALV +1.6%, DB +1.5%, ING +1.2%, CCL +1.2%, BCS +1%, VOD +0.9%, SAP +0.8%
Select oil/gas related names showing strength: RDS.A +1.2%, TOT +1.1%, STO +1%
Other news: CBLI +97.9% (disclosed the sale of ~6.46 mln shares of common stock at $3.87 per share to a venture capital investor, raising gross proceeds of $25 mln), MACK +9.1% (Merrimack Pharma and and Baxalta Incorporated (BXLT) report that the New Drug Application for MM-398 has been accepted by the US FDA), TTHI +8.5% (modest recovery pre-mkt following yday's decline), IACI +7.1% (Board has approved the pursuit of an IPO of The Match Group), MHR +4.6% (determined to pursue the sale of 100% of its current equity ownership interest in Eureka Hunter Holdings), NBG +2.3% (cont vol surrounding Greece debt negotiations), LLY +1.8% (reports a favorable UK court ruling in its Alimta vitamin regimen patent lawsuit; also - upgraded to Buy from Neutral at BofA/Merrill), BBRY +1% (provides update on previously announced 12 mln share purchase program), DIS +0.9% (declares first half dividend of $0.66 per share; ~15% increase from prior dividend on an annualized basis), MDLZ +0.8% (favorable mention on Wednesday's Mad Money)
Analyst comments: AMBA +2.1% (target raised to $115 at Stifel), FIT +1.8% (initiated with a Outperform at Leerink Partner), FINL +1.7% (upgraded to Buy from Neutral at B. Riley & Co), MRO +1.3% (upgraded to Buy from Neutral at UBS), FEYE +1.3% (initiated with an Outperform at Wedbush), T +0.9% (upgraded to Buy from Neutral at BofA/Merrill), PFPT +0.8% (initiated with an Outperform at Wedbush)
In reaction to strong earnings/guidance: WGO +11.1%, MLHR +6.7%, (raises dividend 5%), .ACN +1.7%, CMC +0.8%
M&A news: JOEZ +30.6% (PE takeover speculation), MSO +6.3% (may have 5 other bidders looking at the company, according to NYPost)
Select EU related names showing strength: SAN +2%, ALV +1.6%, DB +1.5%, ING +1.2%, CCL +1.2%, BCS +1%, VOD +0.9%, SAP +0.8%
Select oil/gas related names showing strength: RDS.A +1.2%, TOT +1.1%, STO +1%
Other news: CBLI +97.9% (disclosed the sale of ~6.46 mln shares of common stock at $3.87 per share to a venture capital investor, raising gross proceeds of $25 mln), MACK +9.1% (Merrimack Pharma and and Baxalta Incorporated (BXLT) report that the New Drug Application for MM-398 has been accepted by the US FDA), TTHI +8.5% (modest recovery pre-mkt following yday's decline), IACI +7.1% (Board has approved the pursuit of an IPO of The Match Group), MHR +4.6% (determined to pursue the sale of 100% of its current equity ownership interest in Eureka Hunter Holdings), NBG +2.3% (cont vol surrounding Greece debt negotiations), LLY +1.8% (reports a favorable UK court ruling in its Alimta vitamin regimen patent lawsuit; also - upgraded to Buy from Neutral at BofA/Merrill), BBRY +1% (provides update on previously announced 12 mln share purchase program), DIS +0.9% (declares first half dividend of $0.66 per share; ~15% increase from prior dividend on an annualized basis), MDLZ +0.8% (favorable mention on Wednesday's Mad Money)
Analyst comments: AMBA +2.1% (target raised to $115 at Stifel), FIT +1.8% (initiated with a Outperform at Leerink Partner), FINL +1.7% (upgraded to Buy from Neutral at B. Riley & Co), MRO +1.3% (upgraded to Buy from Neutral at UBS), FEYE +1.3% (initiated with an Outperform at Wedbush), T +0.9% (upgraded to Buy from Neutral at BofA/Merrill), PFPT +0.8% (initiated with an Outperform at Wedbush)